Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia.
Department of Dermatology, University of Southern California, Los Angeles, California.
J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043.
There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD.
To assess therapeutic options for patients with psoriasis and concurrent IBD.
A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease, for the period from January 1, 1947, to February 14, 2017. Randomized, controlled, double-blinded studies were selected if available. If not, the next highest level of available evidence was selected.
Of the 2282 articles identified, 132 were selected. Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative; colitis, and Crohn's disease. Ustekinumab has demonstrated efficacy in psoriasis, psoriatic arthritis, and Crohn's disease. Certolizumab has demonstrated efficacy in psoriatic arthritis and Crohn's disease. Etanercept, secukinumab, brodalumab, and ixekizumab have demonstrated efficacy in psoriasis and psoriatic arthritis but may exacerbate or induce IBD. Guselkumab has demonstrated efficacy in psoriasis.
There are no known clinical trials of treatment specifically for concurrent psoriasis and IBD.
Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.
银屑病与炎症性肠病（IBD）之间存在显著关联。许多用于治疗银屑病和银屑病关节炎的药物也用于治疗 IBD。
评估同时患有银屑病和 IBD 的患者的治疗选择。
对 1947 年 1 月 1 日至 2017 年 2 月 14 日期间用于治疗银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病的生物制剂和全身性银屑病药物的临床研究进行了系统的文献检索。如果有随机、对照、双盲研究，则选择该研究。如果没有，则选择可用的下一层次最高水平的证据。
在确定的 2282 篇文章中，有 132 篇被选中。英夫利昔单抗和阿达木单抗已被证明在银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病中有效。乌司奴单抗已被证明在银屑病、银屑病关节炎和克罗恩病中有效。 Certolizumab 已被证明在银屑病关节炎和克罗恩病中有效。依那西普、司库奇尤单抗、布罗达umab 和依奇珠单抗已被证明在银屑病和银屑病关节炎中有效，但可能会加重或诱导 IBD。古塞库单抗已被证明在银屑病中有效。
目前尚无专门针对同时患有银屑病和 IBD 的患者的治疗的临床试验。
英夫利昔单抗和阿达木单抗已被证明在银屑病、银屑病关节炎、溃疡性结肠炎和克罗恩病中有效；其他药物已被证明在某些但不是所有这些适应症中有效。
